The increasing use of polypharmacotherapy for refractory mood disorders: 22 Years of study

Journal of Clinical Psychiatry

Volumn 61, Issue 1, 2000, Pages 9-15

  Frye, Mark A ^a,b   Ketter, Terence A ^a,c   Leverich, Gabriele S ^a   Huggins, Teresa ^a   Lantz, Caprice ^a   Denicoff, Kirk D ^a   Post, Robert M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; NIMODIPINE; PIMOZIDE; VALPROATE SEMISODIUM;

AFFECTIVE NEUROSIS; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG USE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

EID: 0033977080     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n0104     Document Type: Article

References (63)

1. Bean RB, Osier Sir W. Aphorisms: From His Bedside Teaching and Writings. Springfield, Ill: Charles C Thomas Publisher; 1951
2. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
3. Post RM, Ketter TA, Denicoff K, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl) 1996;128:115-129
4. Vestergaard P. Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 1992;7:249-259
5. Bowden CL, and the Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271: 918-924
6. Himmelhoch JM, Garfinkel ME. Mixed mania: diagnosis and treatment. Psychopharmacol Bull 1986;22:613-620
7. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229-233
8. Faedda GL, Baldessarini RJ, Tonen M, et al. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991;148: 1237-1239
9. O'Connell RA, Mayo JA, Flatow L, et al. Outcome of bipolar disorder on long term treatment with lithium. Br J Psychiatry 1991;159:123-129
10. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995;56(suppl 3):19-24
11. Tohen M, Waternaux CM, Tsuang MT, et al. Four year follow-up of twenty-four first episode manic patients. J Affect Disord 1990;19:79-86
12. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment resistant manic depressive illness. J Clin Psychopharmacol 1997;17:185-189
13. Young LT, Joffe R. Gabapentin in bipolar depression: a case series. Biol Psychiatry 1997;42:851-853
14. Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156:1019-1023
15. Frye MA, Ketter TA, Kimbrell TA, et al. Gabapentin and lamotrigine monotherapy in mood disorder. J Clin Psychophamacol. In press
16. Control of tuberculosis in the United States. Joint Statement of the American Thoracic Society, the Centers for Disease Control, and the Infectious Disease Society of America. Respir Care 1993;38:929-939
17. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26:1376-1398
18. Figueroa M, Gehlsen J, Hammon D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993;328: 1226-1229
19. Myers LW, Phillips JT. Polypharmacy in multiple sclerosis. Epilepsy Res 1996;(suppl 11):181-195
20. Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277:1962-1969
21. Calne RY. Immunosuppression in liver transplantation. N Engl J Med 1994;331:1154-1155
22. Ferrendelli JA. Use of rational polypharmacy to treat epilepsy. Epilepsy Res 1996;(suppl 11):239-243
23. US Gabapentin Study Group No. 5. Gahapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298
24. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43:2284-2291
25. Brodie MJ, Yuen AWC. 105 Study Group Lamotrigine substitution study: evidence of synergism with sodium valproate. Epilepsy Res 1997;26: 423-432
26. Mandoki M. Lamotrigine/valproate in treatment resistant bipolar disorder in children and adolescents [poster abstract]. Biol Psychiatry 1997;41:93S
27. Walden J, Hesslinger B, Van Calker D, et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996;29:193-195
28. Rapp MS, Kaplan A. Polypharmacy revisited. Can J Psychiatry 1981;26: 569-573
29. Gardos G, Perenyl A, Cole JO. Polypharmacy revisited. McLean Hosp J 1980;3/4:178-195
30. Solomon DA, Keitner GI, Ryan CE, et al. Polypharmacy in bipolar I disorder. Psychopharmacol Bull 1996;32:579-587
31. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12-21
32. Dufresne RL. Issues in polypharmacotherapy: focus of major depression. Psychopharmacol Bull 1996;32:547-553
33. Nelson JC. Combined drug treatment strategies for major depression. Psychiatr Ann 1998;28:197-203
34. Nichol MB, Stimmel GL, Lange SC. Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry 1995;56:60-66
35. Rosholm JU, Hallas J, Gram LF. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients: a prescription database study. Br J Clin Pharmacol 1994;37:533-538
36. Konig W, Rissom R, Kalfoglu G, et al. Long-term therapy of affective disorders: monotherapy or polypharmacy? Pharmacopsychiatry 1988;21: 272-273
37. Sachs GS. Use of clonazepam for bipolar affective disorder. J Clin Psychiatry 1990;51(5, suppl):31-34
38. Wolf ME, Bukowski ED, Conran J, et al. Polypharmacy: a problem of the decade of the nineties. In: New Research Program and Abstracts of the 1995 Annual Meeting of the American Psychiatric Association; May 25, 1995; Miami, Fla. Abstract NR622:222
39. Hallin A, Peselow ED, Barouche F, et al. Prescribing practices for bipolar patients in a clinical setting. In: New Research Program and Abstracts of the 1995 Annual Meeting of the American Psychiatric Association; May 25, 1995; Miami, Fla. Abstract NR126:88
40. Peselow ED, Fieve RR, DiFiglia C, et al. Lithium prophylaxis of bipolar illness: the value of combination treatment. Br J Psychiatry 1994;164: 208-214
41. Joffe RT, Post RM, Ballenger JC, et al. Neuroendocrine effects of the dopamine agonist piribedil in depressed patients. Clin Neuropharmacol 1986;9:448-455
42. Post RM. Jimerson DC, Bunney WE Jr, et al. Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology (Berl) 1980;67:297-305
43. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: preliminary report. Commun Psychopharmacol 1978;2:159-175
44. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of antimanic response to carbamazepine. Psychiatr Res 1987;21:71-83
45. Post RM, Ketter TA, Denicoff K, et al. Assessment of anticonvulsant drugs in patients with bipolar affective illness. In: Hindmarch J, Stonier PD, eds. Human Psychopharmacology, vol 4. Chichester, England: Wiley & Sons; 1993:211-245
46. Pazzaglia PJ, Post RM, Ketter TA, et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol. In press
47. Bunney WE Jr, Hamburg DA. Methods for reliable longitudinal observation of behavior. Am J Psychiatry 1963;9:280-294
48. Leverich GL, Post RM. Life charting the course of bipolar disorder. In: Rush AJ, ed. Current Review of Mood Disorders, Epidemiology, Diagnosis, and Assessment of Mood and Anxiety Disorders. Philadelphia, Pa: Current Medicine; 1996:48-61
49. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-171
50. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull 1993;29:375-381
51. Frye MA, Ketter TA, Altshuler LL, et al. Clozapine in bipolar manic-depression: treatment implications for other atypical antipsychotics. J Affect Disord 1998;48:91-104
52. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152: 1130-1138
53. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987;144:1403-1411
54. Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry 1994; 151:1642-1645
55. Post RM, KetterTA, Pazzaglia PJ, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res 1996;11(suppl):153-180
56. Bourgeois BFD. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin Neuropharmacol 1988;11:348-359
57. Yerby M. Pregnancy, teratogenesis, and epilepsy. Neural Clin 1994;12: 749-771
58. Keck PE, McElroy SL, Strakowski SM, et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997;33:87-91
59. Gershon ES, Hamovit JH, Guroff JJ, et al. Birth-cohort changes in manic and depressive disorders in relatives of bipolar and schizoaffective patients. Arch Gen Psychiatry 1987;44:314-319
60. Klerman GL, Weissman MM. Increasing rates of depression. JAMA 1989; 261:2229-2235
61. McInnis MG, McMahon FJ, Chase GA, et al. Anticipation in bipolar affective disorder. Am J Hum Genet 1993;53:385-390
62. Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull 1990;26:409-427
63. Gulik RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739